Baker McKenzie advised the shareholders of Biopharma on the carve-out of its non-plasma business and its further sale to Stada AG. Arzinger acted as a legal advisor to STADA.
Stada Arzneimittel AG manufactures pharmaceuticals. The Company produces generics (products whose patents have expired), brand-name products, and cancer therapy and other special pharmaceuticals.
The Baker McKenzie team was led by partners Viacheslav Yakymchuk (Picture), head of the Corporate M&A practice group, and Olha Demianiuk, head of the Healthcare & Life Sciences industry group, associates Andrii Finogin, Olha Sviatenka and Khrystyna Penyk in Kyiv, and London-based senior corporate associate Robert Gray. The team also included antitrust and competition partner Oksana Simonova and senior associate Olha Mikheieva.
The team of Arzinger that worked on the project included Partner and Head of Corporate Law practice and M&A Anna Zorya, Managing Partner Timur Bondaryev, Partner Lana Sinichkina, Counsel Oleksander Dyakulych, Senior Associates Tetyana Slabko and Volodymyr Svintsitskyi, Associates Maria Dmytruk, Tetyana Drok and Edem Mensitov.
Involved fees earner: Timur Bondaryev – Arzinger; Maria Dmytruk – Arzinger; Tetyana Drok – Arzinger; Oleksander Dyakulych – Arzinger; Edem Mensitov – Arzinger; Lana Sinichkina – Arzinger; Tetyana Slabko – Arzinger; Volodymyr Svintsitskyi – Arzinger; Anna Zorya – Arzinger; Olha Demianiuk – Baker McKenzie; Andrii Finogin – Baker McKenzie; Olha Mikheieva – Baker McKenzie; Khrystyna Penyk – Baker McKenzie; Oksana Simonova – Baker McKenzie; Olha Sviatenka – Baker McKenzie; Viacheslav Yakymchuk – Baker McKenzie; Robert Gray Jr. – Mayer Brown;